| Withdrawn | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgki NCT01769911 | Fred Hutchinson Cancer Center | N/A |
| Terminated | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non NCT02168907 | Wake Forest University Health Sciences | Phase 1 |
| Completed | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lym NCT02168140 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721 | Morphotek | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Completed | Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma NCT01800838 | Kevin Cooper MD | Phase 1 |
| Terminated | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma NCT01738594 | Northwestern University | Phase 1 |
| Terminated | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037 | Northwestern University | Phase 1 / Phase 2 |
| Terminated | Ipilimumab and Local Radiation for Selected Solid Tumors NCT01769222 | Stanford University | Phase 1 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01261247 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT01075321 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Completed | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilizati NCT01110135 | University of Washington | Phase 2 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin L NCT01116154 | City of Hope Medical Center | Phase 1 |
| Completed | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01129180 | Pierluigi Porcu | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory NCT00601718 | University of Washington | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Terminated | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid NCT00354185 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma NCT00112723 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas NCT00089271 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00077155 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Trea NCT00072514 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides NCT00052377 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | 506U78 in Treating Patients With Lymphoma NCT00005080 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma NCT00005982 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymph NCT01678443 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease NCT00003210 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |